Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Budesonide

FDA-approved product (aerosol, metered, nasal), marketed as Budesonide, Entocort Ec, Eohilia and 8 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Budesonide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Allergic rhinitis
  • Asthma
  • Chronic bronchitis
  • Chronic obstructive pulmonary disease
  • Crohn's disease
  • Emphysema
  • Esophageal disease
  • IGA glomerulonephritis
  • Nasal congestion
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis
  • Ulcerative colitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids acting locally; Corticosteroids, potent (group iii); Corticosteroids; Glucocorticoids
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis44.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Budesonide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Budesonide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult Subjects

    NCT05519514 · start 2021-07-12

    Registered record
    Registry ID
    NCT05519514
    Conditions
    Healthy Subjects; Human Volunteers; Healthy Participants; Bioequivalence
    Interventions
    Cortiment; Budesonide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-07-12
    Completion
    2021-11-15
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects; Human Volunteers; Healthy Participants; Bioequivalence
    InterventionCortiment; Budesonide
    PhasePhase 1
    Registry statusCompleted

  • Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms

    NCT04727424 · start 2021-01-19

    Registered record
    Registry ID
    NCT04727424
    Conditions
    Covid19; SARS-Associated Coronavirus
    Interventions
    Spirulin Platensis; Budesonide Powder; Fluoxetine 20 MG; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-01-19
    Completion
    2024-07-01
    Enrolment
    7,819

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19; SARS-Associated Coronavirus
    InterventionSpirulin Platensis; Budesonide Powder; Fluoxetine 20 MG; Placebo
    PhasePhase 3
    Registry statusUnknown

  • Epigenetic Health Benefits of Budesonide

    NCT04342039 · start 2021-01-07

    Registered record
    Registry ID
    NCT04342039
    Conditions
    Epigenetic Effects of Intranasal Steroids; Environmental Exposure
    Interventions
    Budesonide Nasal; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2021-01-07
    Completion
    2027-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpigenetic Effects of Intranasal Steroids; Environmental Exposure
    InterventionBudesonide Nasal; Placebo
    PhasePhase 4
    Registry statusActive not recruiting

  • Effects of Nasal-spraying LiveSpo Navax in Treatment of Influenza Virus in Children

    NCT05378022 · start 2020-12-21

    Registered record
    Registry ID
    NCT05378022
    Conditions
    Acute Respiratory Tract Infections
    Interventions
    LiveSpo Navax; 0.9% NaCl physiological saline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-12-21
    Completion
    2022-04-22
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Respiratory Tract Infections
    InterventionLiveSpo Navax; 0.9% NaCl physiological saline
    PhaseNot applicable
    Registry statusCompleted

  • STerOids in COVID-19 Study

    NCT04416399 · start 2020-07-16

    Registered record
    Registry ID
    NCT04416399
    Conditions
    Coronavirus Infection
    Interventions
    Budesonide dry powder inhaler
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-07-16
    Completion
    2021-01-12
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection
    InterventionBudesonide dry powder inhaler
    PhasePhase 2
    Registry statusTerminated

  • As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period

    NCT04215848 · start 2020-04-01

    Registered record
    Registry ID
    NCT04215848
    Conditions
    Asthma
    Interventions
    Budesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder; Budesonide 200Mcg Inhalation Powder
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-04-01
    Completion
    2022-05-30
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionBudesonide/Formoterol Fumarate 160 MCG-4.5 MCG Inhalation Powder; Budesonide 200Mcg Inhalation Powder
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting

  • Busonid® (Budesonide 200 mcg and 400 mcg) to Treat Asthma Not Controlled or Partially Controlled

    NCT02853578 · start 2019-12

    Registered record
    Registry ID
    NCT02853578
    Conditions
    Asthma
    Interventions
    Busonid (budesonide 200mcg and 400mcg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Suspended
    Start
    2019-12
    Completion
    2020-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionBusonid (budesonide 200mcg and 400mcg)
    PhasePhase 3
    Registry statusSuspended

  • Impact of Budesonide Irrigations on Patients With Chronic Rhinosinusitis and Impact on Sinus Surgery Rates

    NCT03519061 · start 2019-08-13

    Registered record
    Registry ID
    NCT03519061
    Conditions
    Chronic Sinus Infection; Chronic Sinusitis; Chronic Sinusitis - Ethmoidal, Posterior; Chronic Sinus Congestion
    Interventions
    Budesonide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Withdrawn
    Start
    2019-08-13
    Completion
    2019-10-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Sinus Infection; Chronic Sinusitis; Chronic Sinusitis - Ethmoidal, Posterior; Chronic Sinus Congestion
    InterventionBudesonide
    PhasePhase 2 / Phase 3
    Registry statusWithdrawn

  • Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray

    NCT03755557 · start 2018-11-19

    Registered record
    Registry ID
    NCT03755557
    Conditions
    Allergic Rhinitis; Allergic Conjunctivitis; Hayfever
    Interventions
    Rhinocort; Budesolv; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-11-19
    Completion
    2019-04-05
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Rhinitis; Allergic Conjunctivitis; Hayfever
    InterventionRhinocort; Budesolv; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.

    NCT03521063 · start 2018-01-01

    Registered record
    Registry ID
    NCT03521063
    Conditions
    Bronchopulmonary Dysplasia; Infant,Premature; Respiratory Distress Syndrome
    Interventions
    Budesonide; Poractant Alfa; Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-01-01
    Completion
    2019-12-31
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchopulmonary Dysplasia; Infant,Premature; Respiratory Distress Syndrome
    InterventionBudesonide; Poractant Alfa; Saline
    PhasePhase 4
    Registry statusUnknown

  • Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

    NCT03219866 · start 2017-10-03

    Registered record
    Registry ID
    NCT03219866
    Conditions
    COPD; COPD Exacerbation
    Interventions
    Nebulizers; Dry Powder Inhaler; Brovana; Pulmicort; Atrovent; Advair Diskus; Spiriva HandiHaler
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-10-03
    Completion
    2020-04-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD; COPD Exacerbation
    InterventionNebulizers; Dry Powder Inhaler; Brovana; Pulmicort +3 more
    PhasePhase 4
    Registry statusTerminated

  • Asthma Research in Children and Adolescents

    NCT04480242 · start 2017-07-26

    Registered record
    Registry ID
    NCT04480242
    Conditions
    Persistent Asthma; Asthma in Children; Asthma Exacerbation
    Interventions
    Inhaled Corticosteroids (ICs); Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA); Other treatments; Inhaler device; Regularly monitoring of the Inhalation technique through mobile app
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2017-07-26
    Completion
    2030-12-31
    Enrolment
    525

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPersistent Asthma; Asthma in Children; Asthma Exacerbation
    InterventionInhaled Corticosteroids (ICs); Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA); Other treatments; Inhaler device +1 more
    PhaseNot recorded
    Registry statusActive not recruiting

  • Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects

    NCT03075267 · start 2017-04-17

    Registered record
    Registry ID
    NCT03075267
    Conditions
    Chronic Obstructive Pulmonary Disease
    Interventions
    PT010 (BGF MDI) 320/14.4/9.6 µg; PT010 (BGF MDI) 160/14.4/9.6 µg; PT003 (GFF MDI) 14.4/9.6 µg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-04-17
    Completion
    2017-09-05
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease
    InterventionPT010 (BGF MDI) 320/14.4/9.6 µg; PT010 (BGF MDI) 160/14.4/9.6 µg; PT003 (GFF MDI) 14.4/9.6 µg
    PhasePhase 1
    Registry statusCompleted

  • A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects

    NCT04032834 · start 2017-02-20

    Registered record
    Registry ID
    NCT04032834
    Conditions
    Asthma
    Interventions
    VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece; VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask; 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece; 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask; 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece; 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-02-20
    Completion
    2017-05-22
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionVR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece; VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask; 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece; 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask +2 more
    PhasePhase 1
    Registry statusCompleted